Document is current
Any future updates will be listed below
-
Authors
Yulug, Burak
Altay, Ozlem
Li, Xiangyu
Hanoglu, Lutfu
Cankaya, Seyda
Lam, Simon
Velioglu, Halil Aziz
Yang, Hong
Coskun, Ebru
Idil, Ezgi
Nogaylar, Rahim
Ozsimsek, Ahmet
Bayram, Cemil
Bolat, Ismail
Oner, Sena
Tozlu, Ozlem Ozdemir
Arslan, Mehmet Enes
Hacimuftuoglu, Ahmet
Yildirim, Serkan
Arif, Muhammad
Shoaie, Saeed
Zhang, Cheng
Nielsen, Jens
Turkez, Hasan
Borén, Jan
Uhlén, Mathias
Mardinoglu, Adil
-
Funding
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse (72110)
Royal Institute of Technology
- License Information
-
More Information
Article History
Received: 24 October 2022
Accepted: 9 January 2023
First Online: 26 January 2023
Declarations
:
: Written informed consent was obtained from all participants before initiating any trial-related procedures. The trial was conducted following Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. The ethics committee approved the study of Istanbul Medipol University, Istanbul, Turkey (Date:22.01.2020, Decision No: 7), and registered at with Clinical Trial ID: NCT04044131.
: Written informed consent for publication was obtained from all participants before initiating any trial-related procedures.
: AM, JB and MU are the founder and shareholders of ScandiBio Therapeutics. The other authors declare no competing interests.
